Company intelligence / Profile preview
Biotest AG
Dreieich, Hessen, Germanybiotest.com ↗
- Ownership
- Public · BIO
- Employees
- ~2495
- Development stage
- Other
01
Overview
Biotest AG develops and markets plasma protein products and biotherapeutic drugs. Its portfolio includes approved therapies for immune deficiencies and bleeding disorders. Recent milestones include FDA approval of Yimmugo for primary antibody deficiencies in 2024.
- Therapeutic areas
- OtherHematologyImmunology
- Modalities
- Plasma-derived proteins (immunoglobulins, clotting factors, albumin)monoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
17 assets16 more assets in the full pipeline.
03
Partnerships
Kedrion Biopharma Inc. for U.S. commercialization/distribution of Yimmugo® [2024]Distribution partners worldwide across Europe/North America/South America/Asia/Middle East/Africa
Beyond the preview
Go deeper on Biotest AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biotest AG.